Wierda WG - Search Results

1

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Guièze R, et al. Among authors: wierda wg. Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19. Cancer Cell. 2019. PMID: 31543463 Free PMC article.

2

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.

Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Tsimberidou AM, et al. Cancer. 2003 Apr 1;97(7):1711-20. doi: 10.1002/cncr.11238. Cancer. 2003. PMID: 12655528 Free article.

3

In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.

Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. Battle TE, et al. Among authors: wierda wg. Clin Cancer Res. 2003 Jun;9(6):2166-72. Clin Cancer Res. 2003. PMID: 12796382

4

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.

Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Scappini B, et al. Among authors: wierda wg. Cancer. 2004 Apr 1;100(7):1459-71. doi: 10.1002/cncr.20131. Cancer. 2004. PMID: 15042680 Free article.

5

Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.

Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Tsimberidou AM, et al. Among authors: wierda wg. Cancer. 2004 May 15;100(10):2195-200. doi: 10.1002/cncr.20252. Cancer. 2004. PMID: 15139064 Free article.

6

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.

Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Tsimberidou AM, et al. Among authors: wierda wg. Cancer. 2004 Jun 15;100(12):2583-91. doi: 10.1002/cncr.20264. Cancer. 2004. PMID: 15197800 Free article. Clinical Trial.

7

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.

Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. Wierda W, et al. Cancer. 2006 Jan 15;106(2):337-45. doi: 10.1002/cncr.21554. Cancer. 2006. PMID: 16353201 Free article.

8

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Kantarjian H, et al. Cancer. 2006 Mar 1;106(5):1090-8. doi: 10.1002/cncr.21723. Cancer. 2006. PMID: 16435386 Free article.

9

Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.

Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Tsimberidou AM, et al. Among authors: wierda wg. Cancer. 2006 Jul 1;107(1):125-35. doi: 10.1002/cncr.21931. Cancer. 2006. PMID: 16700034 Free article.

10

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.

Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Tsimberidou AM, et al. Among authors: wierda wg. J Clin Oncol. 2008 Jan 10;26(2):196-203. doi: 10.1200/JCO.2007.11.8513. J Clin Oncol. 2008. PMID: 18182662 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

527 results

Search Page